New biologic FB102 takes on celiac disease in Mid-Stage trial

NCT ID NCT06982963

Recruiting now Disease control Sponsor: Forte Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new biologic drug called FB102 in 100 adults with celiac disease who already follow a strict gluten-free diet. Participants will receive either FB102 or a placebo and then undergo a controlled gluten challenge to see if the drug can reduce intestinal damage and symptoms. The goal is to find a better way to manage accidental gluten exposure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FB102 (a biologic drug given by infusion or injection)
What this could lead to: If it works, this could point toward a new treatment to help people with celiac disease better manage their condition even when accidentally exposed to gluten.
What could go wrong: This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not show benefit or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELIAC DISEASE

Contacts and locations

Locations

The Royal Melbourne Hospital
RECRUITING

Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.